OST-tADC Platform
Various Solid Tumors
Pre-clinicalTechnology Development
Key Facts
About OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |